Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure

Highlights•This study highlights the association between prospectively confirmed SNRI treatment remission and genetic polymorphisms in CYP2D6, CYP2C19, SLC6A4, and SLC6A2 in MDD patients with prospectively confirmed prior SSRI treatment failure. •Pharmacokinetic and Pharmacodynamic interaction is as...

Full description

Saved in:

Bibliographic Details
Published in	Journal of affective disorders Vol. 246; pp. 62 - 68
Main Authors	Ahmed, Ahmed T, Biernacka, Joanna M, Jenkins, Gregory, Rush, A John, Shinozaki, Gen, Veldic, Marin, Kung, Simon, Bobo, William V, Hall-Flavin, Daniel K, Weinshilboum, Richard M, Wang, Liewei, Frye, Mark A
Format	Journal Article
Language	English
Published	Netherlands Elsevier B.V 01.03.2019
Subjects	Adult Antidepressive Agents - pharmacokinetics Antidepressive Agents - therapeutic use Citalopram - therapeutic use CYP2D6 Cytochrome P-450 CYP2C19 - metabolism Cytochrome P-450 CYP2D6 - metabolism Depressive Disorder, Major - drug therapy Depressive Disorder, Major - genetics Depressive Disorder, Major - metabolism Female Genotype Humans Logistic Models Male Middle Aged Norepinephrine Plasma Membrane Transport Proteins - genetics Pharmacodynamic-pharmacokinetic interaction Phenotype Psychiatric/Mental Health Remission Serotonin Plasma Membrane Transport Proteins - genetics Serotonin Uptake Inhibitors - pharmacokinetics Serotonin Uptake Inhibitors - therapeutic use SLC6A2 SLC6A4 Treatment Failure Venlafaxine Hydrochloride - pharmacokinetics Venlafaxine Hydrochloride - therapeutic use Venlafaxine-XR Pharmacodynamic-pharmacokinetic interaction Remission Venlafaxine-XR CYP2D6 SLC6A2 SLC6A4
Online Access	Get full text
ISSN	0165-0327 1573-2517 1573-2517
DOI	10.1016/j.jad.2018.12.021

Cover

More Information
Summary:	Highlights•This study highlights the association between prospectively confirmed SNRI treatment remission and genetic polymorphisms in CYP2D6, CYP2C19, SLC6A4, and SLC6A2 in MDD patients with prospectively confirmed prior SSRI treatment failure. •Pharmacokinetic and Pharmacodynamic interaction is associated with venlafaxine-XR treatment remission. •These results underscore the multidimensional aspects of precision medicine as an approach to optimize drug treatment of MDD.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Dr Ahmed, Dr. Frye conceptualized the hypothesis, created the analytic plan, supervised the data analysis, interpreted the results, and drafted the manuscript. Dr Ahmed and Dr. Frye also had access to all data and take responsibility for the accuracy of the data analysis. Dr Ahmed preformed the literature search. Dr. Biernacka and Mr. Jenkins and Dr Ahmed performed the data analysis and interpreted the results. All authors contributed to and approve of the final manuscript. Contributors
ISSN:	0165-0327 1573-2517 1573-2517
DOI:	10.1016/j.jad.2018.12.021